Azitra vs CervoMed
AZTR and CRVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AZTR and CRVO compare
CervoMed is the larger company, worth 6.9 times as much as Azitra ($25.6M against $3.7M).
CervoMed scores higher on the StockData Score (6 against 2 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AZTR | CRVO |
|---|---|---|
| Size and price | ||
| Market cap | $3.7M | $25.6M |
| Share price | $0.608 | $1.69 |
| Change, 1 year | 50.2% | −77.2% |
| Change, 5 years | – | −94.2% |
| Beta (5Y) | −2.26 | 0.55 |
| Employees | 13 | 15 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2928× |
| P/B | 0.8× (better) | 1.5× |
| FCF yield | −316% | – |
| Growth | ||
| Revenue growth (TTM) | – | −99.9% |
| Profitability | ||
| Operating margin | – | −334925% |
| Net margin | – | −326823% |
| Return on equity | −373% | −132% (better) |
| Return on invested capital | −1294% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1220.4× | – |
| Current ratio | 3.11 | 5.37 (better) |
| Altman Z-score | −23.30 | −7.44 (better) |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | −70.9% | – |
| Shareholder yield | −70.9% | 0.00% (better) |
| Ownership | ||
| Held by institutions | – | 11.6% |
| Held by insiders | 95.8% | 36.9% |
| Insider net buying, 12 months | – | $3.0M |
| Short interest, % of float | 121% | 12.7% |
Go deeper
- AZTR stock overview
- AZTR income statement
- AZTR valuation and score
- CRVO stock overview
- CRVO income statement
- CRVO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.